» Articles » PMID: 33623684

Imbalanced Turnover of Collagen Type III is Associated with Disease Progression and Mortality in High-risk Chronic Kidney Disease Patients

Overview
Journal Clin Kidney J
Specialty Nephrology
Date 2021 Feb 24
PMID 33623684
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Tubulointerstitial fibrosis is a major pathological feature in chronic kidney disease (CKD) and collagen type III (COL3) is a major component of the renal fibrotic scar. We hypothesized that a dysregulated turnover of COL3 is an important determinant of CKD progression. We assessed the relationship between fragments reflecting active formation (PRO-C3) and degradation (C3M) of COL3 and CKD disease progression and mortality in a prospective cohort of CKD patients.

Methods: We measured PRO-C3 and C3M in urine (uPRO-C3 and uC3M) and serum (sPRO-C3 and sC3M) of 500 patients from the Renal Impairment in Secondary Care study. Disease progression was defined as a decline in estimated glomerular filtration rate >30% or the start of renal replacement therapy within 12 and 30 months.

Results: Levels of uC3M/creatinine decreased, whereas levels of uPRO-C3/creatinine and sPRO-C3 increased with increasing CKD stage. uC3M/creatinine was inversely and independently associated with disease progression by 12 months {odds ratio [OR] 0.39 [95% confidence interval (CI) 0.18-0.83]; P = 0.01 per doubling of uC3M/creatinine} with development of end-stage renal disease [hazard ratio (HR) 0.70 (95% CI 0.50-0.97); P = 0.03 per doubling of uC3M/creatinine]. sPRO-C3 at baseline was independently associated with increased mortality [HR 1.93 (95% CI 1.21-3.1); P = 0.006 per doubling of sPRO-C3] and disease progression by 30 months [OR 2.16 (95% CI 1.21-3.84); P = 0.009 per doubling of sPRO-C3].

Conclusions: Dynamic products of COL3 formation and degradation were independently associated with CKD progression and mortality and may represent an opportunity to link pathological processes with targeted treatments against fibrosis.

Citing Articles

Collagen type III formation but not degradation is associated with risk of kidney disease progression and mortality after acute kidney injury.

Sparding N, Genovese F, Karsdal M, Selby N Clin Kidney J. 2025; 18(2):sfae413.

PMID: 39927250 PMC: 11806633. DOI: 10.1093/ckj/sfae413.


Research Progress of Fibroblasts in Human Diseases.

Li X, Li N, Wang Y, Han Q, Sun B Biomolecules. 2024; 14(11).

PMID: 39595654 PMC: 11591654. DOI: 10.3390/biom14111478.


Proteomic Analysis Identifies Dysregulated Proteins in Albuminuria: A South African Pilot Study.

Khoza S, George J, Naicker P, Stoychev S, Fabian J, Govender I Biology (Basel). 2024; 13(9).

PMID: 39336107 PMC: 11428484. DOI: 10.3390/biology13090680.


Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?.

Antonella M, Pietrobattista A, Maggiore G Pediatr Rep. 2024; 16(2):288-299.

PMID: 38651464 PMC: 11036198. DOI: 10.3390/pediatric16020025.


Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets.

Reiss A, Jacob B, Zubair A, Srivastava A, Johnson M, Leon J J Clin Med. 2024; 13(7).

PMID: 38610646 PMC: 11012936. DOI: 10.3390/jcm13071881.


References
1.
Nielsen M, Veidal S, Karsdal M, Orsnes-Leeming D, Vainer B, Gardner S . Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. Liver Int. 2014; 35(2):429-37. DOI: 10.1111/liv.12700. View

2.
Marcellin P, Kutala B . Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 2018; 38 Suppl 1:2-6. DOI: 10.1111/liv.13682. View

3.
Hutchison C, Cockwell P, Harding S, Mead G, Bradwell A, Barnett A . Quantitative assessment of serum and urinary polyclonal free light chains in patients with type II diabetes: an early marker of diabetic kidney disease?. Expert Opin Ther Targets. 2008; 12(6):667-76. DOI: 10.1517/14728222.12.6.667. View

4.
Barbour S, Reich H . Risk stratification of patients with IgA nephropathy. Am J Kidney Dis. 2012; 59(6):865-73. DOI: 10.1053/j.ajkd.2012.02.326. View

5.
Genovese F, Manresa A, Leeming D, Karsdal M, Boor P . The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?. Fibrogenesis Tissue Repair. 2014; 7(1):4. PMC: 3986639. DOI: 10.1186/1755-1536-7-4. View